Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #1 top biotech stock out of 637 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 55, which is 32 points higher than the biotech industry average of 23.

AUPH passed 18 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 120.37% over the past year, overperforming other biotech stocks by 185 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $13.00, an upside of 8.24% from Aurinia Pharmaceuticals's current stock price of $12.01.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Aurinia Pharmaceuticals, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Rigel Pharmaceuticals (NASDAQ:RIGL) is the #2 top biotech stock out of 637 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Rigel Pharmaceuticals (NASDAQ:RIGL) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Rigel Pharmaceuticals (NASDAQ:RIGL) has a Due Diligence Score of 40, which is 17 points higher than the biotech industry average of 23.

RIGL passed 13 out of 33 due diligence checks and has average fundamentals. Rigel Pharmaceuticals has seen its stock return 188.71% over the past year, overperforming other biotech stocks by 253 percentage points.

Rigel Pharmaceuticals has an average 1 year price target of $42.00, an upside of 14.82% from Rigel Pharmaceuticals's current stock price of $36.58.

Rigel Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Rigel Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Halozyme Therapeutics (NASDAQ:HALO) is the #3 top biotech stock out of 637 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Halozyme Therapeutics (NASDAQ:HALO) is: Value: A, Growth: B, Momentum: D, Sentiment: B, Safety: C, Financials: A, and AI: B.

Halozyme Therapeutics (NASDAQ:HALO) has a Due Diligence Score of 59, which is 36 points higher than the biotech industry average of 23.

HALO passed 20 out of 33 due diligence checks and has strong fundamentals. Halozyme Therapeutics has seen its stock return 16.32% over the past year, overperforming other biotech stocks by 81 percentage points.

Halozyme Therapeutics has an average 1 year price target of $70.60, an upside of 8.4% from Halozyme Therapeutics's current stock price of $65.13.

Halozyme Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Halozyme Therapeutics, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 4.88%, which is 3 percentage points higher than the biotech industry average of 1.53%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 3.17%, which is 2 percentage points higher than the biotech industry average of 1.53%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 41.4% indicates that its dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.78%, which is the same as the biotech industry average of 1.53%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 37.2% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were up 2.48% in the last day, and up 3.77% over the last week. Generation Bio Co was the among the top gainers in the biotechnology industry, gaining 63.21% yesterday.

Generation Bio shares are trading higher after the company announced new data demonstrating that its cell-targeted lipid nanoparticle system selectively delivered siRNA to T cells in non-human primates.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 43 points higher than the biotech industry average of 14. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 4.5% in the past year. It has overperformed other stocks in the biotech industry by 69 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 46.81% in the past year. It has overperformed other stocks in the biotech industry by 111 percentage points.

United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -4.29% in the past year. It has overperformed other stocks in the biotech industry by 60 percentage points.

53.77% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 92.47% over the next year.

2.74% of biotech stocks have a Zen Rating of A (Strong Buy), 4.64% of biotech stocks are rated B (Buy), 37.34% are rated C (Hold), 33.54% are rated D (Sell), and 21.73% are rated F (Strong Sell).